To test the in vivo therapeutic potential of ATR inhibition in BRCA2 haploinsufficient T-ALL, we first transduced BRCA2-haploinsufficient clone W5 cells with EGFP, and their isogenic parental cells with dTomato. The gene discussed is ATR; the disease is acute lymphoblastic leukemia.